- IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE
-
An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.
- -
-
Paragraph 0145; 0146
(2015/07/15)
-
- IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE
-
An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.
- -
-
Page/Page column 20; 21
(2014/02/16)
-
- Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
-
The present invention relates to diastereomers of 10-propargyl-10-deazaminopterin, compositions comprising optically pure diastereomers of 10-propargyl-10-deazaminopterin, in particular the two (R,S) diastereomers about the C10 position. Methods of preparation of these diastereomers, compositions containing them, and their use for the treatment of conditions related to inflammatory disorders and cancer are also disclosed.
- -
-
Page/Page column 7
(2011/08/08)
-
- Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
-
T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m2. In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m2 per dose.
- -
-
Page/Page column 3; 4; Sheet 2
(2008/06/13)
-